CRVS

Corvus Pharmaceuticals Inc

Oct 17 • 04:00PM ET

7.04

-0.61 -7.97 %

Healthcare • Biotechnology • USA • NASD

Peers: BMY GILD REGN VRTX INCY EXEL BLUE IONS BMRN SRPT

| Held by: VTI IWM VXF IWO IBB VTWO IWC ITOT CANC VTWG

Index	RUT	P/E	-	EPS (ttm)	-1.02	Insider Own	27.01%	Shs Outstand	74.51M	Perf Week	1.59%
Market Cap	524.58M	Forward P/E	-	EPS next Y	-0.56	Insider Trans	-10.47%	Shs Float	54.39M	Perf Month	15.03%
Enterprise Value	451.25M	PEG	-	EPS next Q	-0.13	Inst Own	36.92%	Short Float	18.56%	Perf Quarter	58.20%
Income	-45.13M	P/S	-	EPS this Y	62.04%	Inst Trans	1.51%	Short Ratio	14.57	Perf Half Y	117.28%
Sales	0.00M	P/B	6.54	EPS next Y	-45.76%	ROA	-58.61%	Short Interest	10.10M	Perf YTD	31.59%
Book/sh	1.08	P/C	7.05	EPS next 5Y	17.29%	ROE	-68.67%	52W High	10.00 -29.60%	Perf Year	4.76%
Cash/sh	1.00	P/FCF	-	EPS past 3/5Y	0.38% 8.47%	ROIC	-55.75%	52W Low	2.54 177.17%	Perf 3Y	658.21%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	9.26% 7.50%	Perf 5Y	79.59%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-50.83%	Oper. Margin	-	ATR (14)	0.50	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.91	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	54.46	Recom	1.14
Dividend Gr. 3/5Y	- -	Current Ratio	8.91	EPS Q/Q	-43.98%	SMA20	0.33%	Beta	0.55	Target Price	15.00
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	15.23%	Rel Volume	1.43	Prev Close	7.65
Employees	31	LT Debt/Eq	0.01	Earnings	Aug 07 AMC	SMA200	50.73%	Avg Volume	693.16K	Price	7.04
IPO	Mar 23, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	24.98% -	Trades		Volume	988,452	Change	-7.97%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-13-25	Initiated	Barclays	Overweight	$16
Jan-02-25	Initiated	H.C. Wainwright	Buy	$11
Aug-18-23	Initiated	Oppenheimer	Outperform	$7
Dec-01-21	Resumed	Jefferies	Buy	$8
May-27-21	Initiated	Cantor Fitzgerald	Overweight	$10
Feb-10-21	Downgrade	Mizuho	Buy → Neutral	$7 → $4
Sep-12-19	Initiated	Mizuho	Buy
May-29-19	Initiated	ROTH Capital	Buy	$6
Aug-24-17	Upgrade	Credit Suisse	Underperform → Neutral
May-01-17	Downgrade	Credit Suisse	Neutral → Underperform
Apr-18-16	Initiated	Guggenheim	Buy
Apr-18-16	Initiated	Credit Suisse	Outperform

Show Previous Ratings

Oct-17-25 10:00AM	Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025 (GlobeNewswire) -7.97%
Oct-02-25 04:01PM	Corvus Pharmaceuticals Appoints David Moore to Board of Directors (GlobeNewswire)
Aug-07-25 04:17PM	Corvus: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-01-25 09:00AM	BioMarin Announces Appointment of Ian T. Clark to Board of Directors (PR Newswire)
04:01PM	Loading…
Jul-31-25 04:01PM	Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2025 Financial Results on August 7, 2025 (GlobeNewswire)
Jun-25-25 08:00AM	Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for a Phase 1b/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic Dermatitis (GlobeNewswire) -5.07%
Jun-11-25 07:00AM	Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress (GlobeNewswire) +5.88%
Jun-04-25 07:00AM	Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis (GlobeNewswire) -8.98%
May-28-25 04:01PM	Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference (GlobeNewswire)
May-09-25 08:32AM	Is Corvus Pharmaceuticals, Inc. (CRVS) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey) +32.24%
03:41AM	Corvus Pharmaceuticals Inc (CRVS) Q1 2025 Earnings Call Highlights: A Turnaround with Promising ... (GuruFocus.com)
May-08-25 04:39PM	Corvus: Q1 Earnings Snapshot (Associated Press Finance)
04:02PM	Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results (GlobeNewswire)
04:01PM	Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis (GlobeNewswire)
05:35PM	Loading…
May-07-25 05:35PM	Corvus Pharmaceuticals Q1 2025 Earnings Preview (Seeking Alpha)
Apr-23-25 04:08PM	Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025 (GlobeNewswire) +5.71%
Apr-22-25 06:47PM	Is Corvus Pharmaceuticals, Inc. (CRVS) the Best Multibagger Penny Stock to Buy According to Billionaires? (Insider Monkey)
Apr-09-25 04:01PM	Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors (GlobeNewswire)
Mar-28-25 09:30AM	Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials (Seeking Alpha)
09:29AM	Corvus Pharmaceuticals: Now At Cruising Altitude (Seeking Alpha)
Mar-26-25 10:39AM	Q4 2024 Corvus Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -14.76%
03:02AM	Corvus Pharmaceuticals Inc (CRVS) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Mar-25-25 07:58PM	Corvus Pharmaceuticals, Inc. (CRVS) Q4 2024 Earnings Call Transcript (SeekingAlpha) -7.53%
04:09PM	Corvus: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-20-25 08:00AM	Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma (GlobeNewswire)
Mar-19-25 04:01PM	Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference (GlobeNewswire) -5.76%
Mar-17-25 04:01PM	Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 (GlobeNewswire)
Mar-12-25 08:00AM	Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) (GlobeNewswire) +5.95%
08:00AM	Loading…
Feb-04-25 08:00AM	Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire) +5.33%
Jan-13-25 07:30AM	Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis (GlobeNewswire)
Jan-07-25 04:01PM	Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-24 01:23PM	Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday? (Benzinga) -36.40%
07:30AM	Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis (GlobeNewswire)
06:45AM	Tessera gets sickle cell funding; Corvus shares slide on eczema data (BioPharma Dive)
Dec-17-24 04:01PM	Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024 (GlobeNewswire) +7.10%
Dec-04-24 04:05PM	Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity (GlobeNewswire)
Nov-14-24 10:01AM	Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis (GlobeNewswire)
Nov-13-24 02:18AM	Corvus Pharmaceuticals Inc (CRVS) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid ... (GuruFocus.com)
Nov-12-24 04:13PM	Corvus: Q3 Earnings Snapshot (Associated Press Finance) -9.10%
04:01PM	Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-09-24 01:40PM	Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer (GlobeNewswire)
Nov-05-24 04:02PM	Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024 (GlobeNewswire)
Sep-10-24 08:30AM	Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (GlobeNewswire) +13.88%
Sep-03-24 04:05PM	Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -9.82%
Aug-06-24 04:15PM	Corvus: Q2 Earnings Snapshot (Associated Press Finance) +6.38% +9.67%
04:01PM	Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-01-24 08:30AM	Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) (GlobeNewswire) +16.34%
Jul-31-24 08:30AM	Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024 (GlobeNewswire)
Jul-25-24 08:30AM	Publication of Preclinical Data in Science Signaling Demonstrated the Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Treatment of Inflammatory Diseases (GlobeNewswire) +6.45%
May-31-24 10:00AM	The 2024 Millionaire's Club: 3 Penny Stocks to Buy Now (InvestorPlace)
May-30-24 04:02PM	Corvus Pharmaceuticals to Present at the Jefferies Global Health Conference (GlobeNewswire)
May-12-24 03:26PM	13 Penny Stocks with Insider Buying in 2024 (Insider Monkey)
May-07-24 05:12PM	Corvus Pharmaceuticals Insider Bought Shares Worth $1,000,000, According to a Recent SEC Filing (MT Newswires) -12.04% +16.67%
11:07AM	Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q1 2024 Earnings Call Transcript (Insider Monkey)
06:35AM	Q1 2024 Corvus Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
03:09AM	Corvus Pharmaceuticals Inc (CRVS) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-06-24 08:58PM	CRVS Stock Earnings: Corvus Pharma Misses EPS for Q1 2024 (InvestorPlace)
04:21PM	Corvus: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-02-24 04:02PM	Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024 (GlobeNewswire) +7.45% +10.98%
08:30AM	Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering (GlobeNewswire)
Apr-17-24 09:35AM	Here's Why Corvus (CRVS) is Poised for a Turnaround After Losing -25% in 4 Weeks (Zacks) -7.48%
Apr-09-24 04:01PM	Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis (GlobeNewswire) -7.36%
Apr-01-24 09:35AM	Down -18.35% in 4 Weeks, Here's Why Corvus (CRVS) Looks Ripe for a Turnaround (Zacks)
Mar-22-24 12:00PM	Corvus (CRVS) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Mar-21-24 09:48AM	Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-20-24 06:32AM	Q4 2023 Corvus Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -5.61%
Mar-19-24 04:08PM	Corvus: Q4 Earnings Snapshot (Associated Press Finance)
04:02PM	Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-13-24 04:02PM	Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024 (GlobeNewswire) -6.00%
Feb-12-24 09:22AM	Corvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock Up (Zacks)
08:30AM	Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases (GlobeNewswire)
Feb-08-24 04:05PM	Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma (GlobeNewswire) +10.75%
Feb-06-24 04:05PM	Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer (GlobeNewswire)
Jan-23-24 05:00PM	Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell (GlobeNewswire)
Dec-11-23 12:00PM	What Makes Corvus (CRVS) a New Buy Stock (Zacks) -16.15%
Dec-09-23 12:00PM	Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial (GlobeNewswire)
Dec-07-23 09:40AM	Are Medical Stocks Lagging Corvus Pharmaceuticals (CRVS) This Year? (Zacks)
Nov-21-23 09:40AM	Is Corvus Pharmaceuticals (CRVS) Stock Outpacing Its Medical Peers This Year? (Zacks) -6.67%
Nov-08-23 11:56AM	Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q3 2023 Earnings Call Transcript (Insider Monkey)
08:43AM	Q3 2023 Corvus Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-07-23 04:32PM	Corvus: Q3 Earnings Snapshot (Associated Press Finance) +6.76%
04:01PM	Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-02-23 09:15AM	Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition (GlobeNewswire)
Nov-01-23 07:31PM	Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases (GlobeNewswire)
Oct-31-23 04:02PM	Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023 (GlobeNewswire)
Sep-06-23 04:05PM	Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA (GlobeNewswire) -21.53%
Aug-30-23 10:01AM	2 Strong Buy Stocks Under $10 That Oppenheimer Sees Surging Over 200% Heres Why They Could Jump (TipRanks) +12.14%
Aug-08-23 04:35PM	Corvus: Q2 Earnings Snapshot (Associated Press Finance) +7.94%
04:01PM	Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-01-23 08:30AM	Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023 (GlobeNewswire)
Jul-06-23 12:59PM	Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential Novel Approach to Immunotherapy Based on Inhibition of ITK with Soquelitinib (CPI-818) (GlobeNewswire)
Jun-29-23 07:00AM	Corvus Pharmaceuticals Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference (GlobeNewswire) -5.11%
Jun-15-23 07:00AM	Corvus Pharmaceuticals Presents New CPI-818 Interim Data at the International Conference on Malignant Lymphoma (GlobeNewswire) -25.67%
Jun-04-23 08:10AM	Individual investors among Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) largest shareholders, saw gain in holdings value after stock jumped 23% last week (Simply Wall St.)
May-31-23 08:30AM	Corvus Pharmaceuticals to Present at the Jefferies Healthcare Conference (GlobeNewswire)
08:11AM	3 High-Potential Penny Stocks to Buy Now (InvestorPlace)
May-26-23 09:40AM	Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year? (Zacks) -7.14%

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ORBIMED ADVISORS LLC	Director	Jun 27 '25	Sale	4.16	1,176,332	4,891,894	7,165,006	Jul 01 09:23 PM
Thompson Peter A.	Director	Jun 27 '25	Sale	4.16	1,176,332	4,891,894	7,165,006	Jul 01 09:17 PM
Jones William Benton	See Remarks	Jun 04 '25	Option Exercise	3.50	19,357	67,750	173,130	Jun 06 04:26 PM
MILLER RICHARD A MD	President and CEO	May 07 '25	Option Exercise	3.50	559,073	1,956,756	1,136,707	May 09 04:09 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CRVS

Corvus Pharmaceuticals Inc

Upgrade your FINVIZ experience